Understanding a patient’s genetic make-up allows a physician to predict how a prescribed drug will relate with that patient, giving the clinician insight into not only clinical efficacy, but also potential undesired drug reactions.
  • How well does the patient metabolize drugs and what personal factors are being used to aid in drug selection?

    Pharmacogenetic Test (PGx) acts as a lifelong prescribing roadmap, steering the provider towards drugs that are metabolized efficiently and away from those that are not.

  • Is there a system to identify when a patient is taking a medication that is poorly suited for them?

    PGx acts as a safeguard, protecting both physician and patient from undesirable adverse drug reactions.

  • How can a physician mitigate drug-drug interactions when a patient is prescribed multiple medications?

    PGx flags potentially dangerous interactions between drugs and often suggests suitable alternatives.

  • Why Test?

    Patients have differences in DNA that impact drug metabolism which may increase their likelihood of an adverse drug reaction:

    More than 85% of the population has detectable variations in their DNA that increase their risk for adverse drug reactions.
    Adverse drug reactions are the 4th leading cause of death nationwide with more than 8.6 million cases reported annually.
    The FDA highlights pharmacogenomics data for more than 130 prescription medications, indicating their strong support for testing.

  • Who To Test?

    The FDA highlights pharmacogenomics data for more than 130 prescription medications, indicating their strong support for testing.
    Patients that experience less than optimal results from prescribed medications.
    Patients with a personal or family history of adverse drug reactions in response to certain medications.
    Polypharmacy patients; those taking multiple prescription medications for multiple chronic conditions.

FDA studies estimate that 7% of hospitalized patients have a serious adverse drug reaction with a fatality rate of 0.32%.
There are more than 2,216,000 serious ADRs in hospitalized patients, causing over 106,000 deaths annually.